Submission Details
| 510(k) Number | K162451 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | September 01, 2016 |
| Decision Date | November 28, 2016 |
| Days to Decision | 88 days |
| Submission Type | Traditional |
| Review Panel | Microbiology (MI) |
| Summary | Summary PDF |
K162451 is an FDA 510(k) clearance for the Solana HSV 1+2/VZV Assay, a Herpes Virus (vzv, Hsv1, Hsv2), Dna Detection Assay For Cutaneous And Mucocutaneous Lesion Samples (Class II — Special Controls, product code PGI), submitted by Quidel Corporation (Athens, US). The FDA issued a Cleared decision on November 28, 2016, 88 days after receiving the submission on September 1, 2016. This device falls under the Microbiology review panel. Regulated under 21 CFR 866.3309.
| 510(k) Number | K162451 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | September 01, 2016 |
| Decision Date | November 28, 2016 |
| Days to Decision | 88 days |
| Submission Type | Traditional |
| Review Panel | Microbiology (MI) |
| Summary | Summary PDF |
| Product Code | PGI — Herpes Virus (vzv, Hsv1, Hsv2), Dna Detection Assay For Cutaneous And Mucocutaneous Lesion Samples |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 866.3309 |
| Definition | For The Qualitative Detection And Differentiation Of Vzv, Hsv1, Hsv2- Dna In Cutaneous And Mucocutaneous Lesion Samples From Symptomatic Patients. The Assay Is Not Intended For Use With Cerebral Spinal Fluid. |